Chief Medical Officer Directorate
Pharmacy and Medicines Division

Scottish Government
Riaghaltas na h-Alba
gov.scot

T: 0131-244-2528
E: irene.fazakerley@gov.scot

IMMEDIATE MESSAGE TO:

1. Directors of Pharmacy
2. Medical Directors NHS Boards

15 April 2024

Dear Healthcare Professional,

DRUG ALERT CLASS 3 DRUG ALERT 13 2024 – CLASS 3 MEDICINES RECALL – ACTION WITHIN 5 DAYS – A MENARINI FARMACEUTICA INTERNAZIONALS SRL – INVOKANA 300MG TABLETS (NORTHERN IRELAND ONLY)

Please see drug alert for onward transmission as below

Could all Directors of Pharmacy please forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Primary Care Pharmacists

Please could Medical Directors arrange to forward this alert on to:-

- General Practitioners
- Accident & Emergency Departments
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

IRENE FAZAKERLEY
Medicines Policy Team

Medicines & Healthcare products Regulatory Agency

MEDICINES RECALL

CLASS 3 MEDICINES RECALL

Action Within 5 Days
Pharmacy/Wholesaler Level Recall

Date: 16 April 2024 EL (24)A/13 Our Ref: MDR 105-04/24

Dear Healthcare Professional,

A. Menarini Farmaceutica Internazionale Srl

Invokana 300mg tablets (Northern Ireland only) EU/1/13/884/006

SNOMED Code 24088311000001106

Batch No	Expiry Date	Pack Size	First Distributed
NDL0N00	31/03/2026	30 tablets	8 March 2024

Active Pharmaceutical Ingredient: Canagliflozin hemihydrate

Brief description of the problem
A. Menarini Farmaceutica Internazionale Srl is recalling the above batch as a precautionary measure due to the distribution of Invokana 300mg in Northern Ireland in packaging intended for the Greek market.

This affects Invokana 300mg (30 tablets) in Northern Ireland only.

Advice for healthcare professionals
Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

Advice for patients
No further action is required by patients as this is a Pharmacy and Wholesaler level recall. Patients should continue to take medicines from these batches as prescribed by your healthcare professional.

Patients who experience adverse reactions or have any questions about the medication, should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Further Information
For medical information enquiries please contact menarini@medinformation.co.uk.

For stock control enquiries please contact rmillward@menariniuk.com.

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

Medicines & Healthcare products Regulatory Agency

Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574
DMRC@mhra.gov.uk